Galderma Group AG
GALD
Rank in Stocks
#459
Galderma Group AG operates as a dermatology company worldwide. The company... Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
Share Price
$224.81
Market Cap
$52.42B
Change (1 day)
6.31%
Change (1 year)
31.28%
Country
CH
Trade Galderma Group AG (GALD)
Category
Healthcare
P/S ratio for Galderma Group AG (GALD)
P/S ratio as of October 2026 TTM: 8.92
According to Galderma Group AG latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 8.92. At the end of 2024 the company had a P/S ratio of 5.38.
P/S ratio history for Galderma Group AG from 2021 to 2026
P/S ratio at the end of each year
| Year | P/S Ratio | Change |
|---|---|---|
| 2026 (TTM) | 8.92 | -3.45% |
| 2025 | 9.24 | 71.63% |
| 2024 | 5.38 | 56.84% |
| 2023 | 3.43 | -2.09% |
| 2022 | 3.51 | -13.02% |
| 2021 | 4.03 | 0.00% |
P/S ratio for similar companies or competitors
| Company | P/S Ratio | P/S Ratio Difference | Country |
|---|---|---|---|
| 2.82 | -68.43% |
DE
|
|
| 3.02 | -66.17% |
DE
|
|
| 2.19 | -75.49% |
JP
|
|
| 7.04 | -21.08% |
IN
|
|
| 9.37 | 5.01% |
CN
|
